IP Addendum-2016 to IP-2014 has been released on 14.11.2015 by Sh. J.P. Nadda, Hon’ble Minister of Health & Family Welfare Government of India in the presence of the guest of honour, Gen. (Dr.) V. K. Singh (Retd.), Minister of State for - External Affairs, Indian Overseas Affairs, Statistics & Programme Implementation (I/c), Government of India along with senior officers of Ministry of Health & Family Welfare and Scientific Staff of Indian Pharmacopoeia Commission, Ghaziabad.
The Indian Pharmacopoeia (IP) is published in fulfillment of the requirements of the Drugs and Cosmetics Act, 1940 and Rules thereunder. It prescribes the standards for drugs produced and/or marketed in India and thus contributes in the control and assurance of the quality of the medicines. The standards of this pharmacopoeia are authoritative and legally enforceable. It intends to help in the licensing of manufacturing units, inspection and distribution of medicines.
The Addendum 2016 of the Indian Pharmacopoeia 2014 is published by the Indian Pharmacopoeia Commission (IPC) on behalf of the Government of India, Ministry of Health & Family Welfare and will be effective from 1st January 2016.
Indian Pharmacopoeia is published in continuing pursuit of the mission of IPC to improve the health of the people through ensuring the quality, safety and efficacy of medicines. The Commission has been receiving significant inputs from regulatory, industrial houses, academic institutions, national laboratories, individual scientists and others.
Keeping in view of the common health of the Indian population, IP Addendum 2016 comprises various categories of drugs such as Antiviral, Anticancer, Antibacterial, Antihypertensive, Antidepressant and Analgesic etc. Indian Pharmacopoeia Commission by including new monographs in this addendum trying to boost public confidence in relation to quality of medicines for domestic and overseas use.
Addendum 2016 to IP 2014 incorporates 89 New Monographs consisting of 64 Chemical Monographs, 14 Herbal Monographs, 03 Vaccines and Immunsera for Human use, 03 Radiopharmaceuticals Monographs, 01 Blood Related Products, 04 Biotechnology Products Monographs and 02 General Chapter being included in this addendum. It is assured that this addendum would play a significant role in improving the quality of medicines which in turn promote public health and accelerate the growth and development of Pharma sector.
Left to Right: Dr. G. N. Singh, Secretary-cum-Scientific Director, IPC; Padmashree Dr. Nitya Anand,Scientist; Dr. Jagdish Prasad, Director General, DGHS, MoH&FW; Shri J. P. Nadda, Hon’ble Minister of Health & Family Welfare, GOI, Gen. (Dr.) V. K. Singh (Retd.), Minister of State for - External Affairs, Indian Overseas Affairs, Statistics & Programme Implementation (I/c); Shri K. L. Sharma, Joint Secretary(R), MoH&FW; Prof. B. Suresh, Chairman, SB, IPC